Palisade Bio (PALI) Debt Ratio (2013 - 2025)

Palisade Bio (PALI) posted quarterly Debt Ratio of 0.03 for Q3 2025, up 240.44% quarter-over-quarter from 0.01 in Q2 2025.

Palisade Bio (PALI) Debt Ratio (2013 - 2025) Analysis & Trends

Palisade Bio (PALI) has reported Debt Ratio for 10 consecutive years, with 0.03 the latest figure, recorded in Q3 2025.

In Q3 2025, Debt Ratio changed N/A year-over-year to 0.03; the TTM figure through Sep 2025 stood at 0.03 (changed N/A YoY), while the FY2023 annual figure was 0.01, changed N/A from the prior year.
Debt Ratio climbed to 0.03 in Q3 2025 per PALI's latest filing, from 0.01 in the prior quarter.
Across five years, Debt Ratio topped out at 0.08 in Q2 2021 and bottomed at 0.01 in Q4 2021.
Historically, Debt Ratio has averaged 0.02 across 4 years, with a median of 0.01 in 2023.
Annual changes were most pronounced in 2021 — Debt Ratio plunged 98.16% — and 2025, when it decreased 14.49%.
Palisade Bio's Debt Ratio stood at 0.01 in 2021, then jumped by 46.35% to 0.01 in 2023, then gained by 13.76% to 0.01 in 2024, then jumped by 191.12% to 0.03 in 2025.
Business Quant data shows PALI's Debt Ratio at 0.03 in Q3 2025, 0.01 in Q2 2025, and 0.01 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.05
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.12
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.47
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.26
10	Palisade Bio	372.94 Mn	247.74 Mn	-	-

Download Data